The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase 3, randomised FDChina study
FDChina (NCT04024462) was a randomised, phase 3 trial of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) versus intravenous pertuzumab plus trastuzumab, in combination with docetaxel, in Chinese patients with HER2-positive early breast cancer in the neoadjuvant and adjuvant settings. We present pharmacokinetic, efficacy and safety results from the primary analysis.